Repurposing of the bisbenzimide antibiotic Ridinilazole as an antiviral compound against human cytomegalovirus
Journal of General Virology · 19.12.2025 · 106 (12)
DOI: 10.1099/jgv.0.002205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of General Virology, erschienen am 19.12.2025. Verfasst von Hayden Pinto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infection & Immunity, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK. Hauptthemen laut MEDLINE: Cytomegalovirus, Antiviral Agents, Drug Repositioning, Anti-Bacterial Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Novel antiviral drugs targeting DNA viruses are desirable. Previous studies from our laboratory and others have demonstrated that DNA binding bisbenzimide compounds are capable of inhibiting replication of diverse DNA viruses, such as a herpesvirus and prototype or pandemic potential poxviruses. To further the aforementioned studies, we sought to identify a bisbenzimide compound that had been successfully administered to humans and repurpose that compound as a broadly acting antiviral compound. We found that the previously described bisbenzimide antibiotic Ridinilazole was a potent inhibitor of human cytomegalovirus (HCMV) at sub-micromolar concentrations, with no obvious effect on cell viability. However, inhibition of virus replication by Ridinilazole was selective, as Ridinilazole had no obvious effect on the replication of another DNA virus (herpes simplex virus) or an RNA virus (influenza). Based upon our bioinformatic analysis of viral genome content, we propose that the number of putative Ridinilazole binding sites in a viral DNA genome is important for the antiviral action of Ridinilazole. Western blotting and electron microscopy revealed that Ridinilazole had no obvious effect on HCMV protein production, but did decrease the number of HCMV capsids in the cytoplasm. Overall, we identified an antibiotic compound previously used in humans that could be repurposed as an antiviral compound to efficaciously inhibit replication of HCMV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Infection & Immunity, St George's School of Health and Medical Sciences, City St George's, University of London, London, UK.
Zitieren
APA
Pinto, H., Latham, K. A., Goodbourn, S., Witney, A. A., & Strang, B. L. (2025). Repurposing of the bisbenzimide antibiotic Ridinilazole as an antiviral compound against human cytomegalovirus. Journal of General Virology, 106(12). https://doi.org/10.1099/jgv.0.002205
Vancouver
Pinto H, Latham KA, Goodbourn S, Witney AA, Strang BL. Repurposing of the bisbenzimide antibiotic Ridinilazole as an antiviral compound against human cytomegalovirus. Journal of General Virology. 2025;106(12). doi:10.1099/jgv.0.002205
BibTeX
@article{Pinto2025,
author = {Pinto, Hayden and Latham, Katie A and Goodbourn, Steve and Witney, Adam A and Strang, Blair L},
title = {Repurposing of the bisbenzimide antibiotic Ridinilazole as an antiviral compound against human cytomegalovirus},
journal = {Journal of General Virology},
year = {2025},
volume = {106},
number = {12},
doi = {10.1099/jgv.0.002205}
}
EUVIMED